BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35792913)

  • 1. LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway.
    Shi W; Ling L; Li C; Wu R; Zhang M; Shao F; Wang Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1295-1311. PubMed ID: 35792913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma.
    Fu J; Pan J; Yang X; Zhang Y; Shao F; Chen J; Huang K; Wang Y
    Cancer Cell Int; 2021 Sep; 21(1):505. PubMed ID: 34544452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma.
    Zhou H; Shen Q; Fu J; Jiang F; Wang L; Wang Y
    J Clin Lab Anal; 2020 Aug; 34(8):e23312. PubMed ID: 32249461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
    Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
    Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
    Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
    J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma.
    Hu L; Chen J; Zhang F; Wang J; Pan J; Chen J; Wang Y
    Biomed Res Int; 2017; 2017():7498151. PubMed ID: 29279851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
    Liu X; Huang Z; Qian W; Zhang Q; Sun J
    J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
    PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.
    Zhao X; Li X; Zhou L; Ni J; Yan W; Ma R; Wu J; Feng J; Chen P
    Cancer Sci; 2018 Oct; 109(10):3068-3079. PubMed ID: 30099826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
    Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
    Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
    Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
    Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of LncRNA-UCA1 Correlates with Lung Adenocarcinoma Progression and Poor Prognosis.
    Chen L; Cao P; Wu Q; Guo Y; Yang Y; Chen F
    Clin Lab; 2019 Mar; 65(3):. PubMed ID: 30868851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inverse interaction between
    Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
    Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
    [No Abstract]   [Full Text] [Related]  

  • 18. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
    Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
    J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
    Zhang Y; Du H; Li Y; Yuan Y; Chen B; Sun S
    Cancer Sci; 2020 Feb; 111(2):637-646. PubMed ID: 31677335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a.
    Du H; Li Y; Sun R; Yuan Y; Sun S; Zhang Y
    Thorac Cancer; 2020 Sep; 11(9):2473-2482. PubMed ID: 32648688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.